Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Boxer Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 81
Average round size
info
The average size of a deal this fund participated in
$90M
Portfolio companies 67
Rounds per year 4.26
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 40
Key employees 3

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Life Science
  • Medical
Summary

The leading representative office of defined VC is situated in the Windermere. The company was established in North America in United States.

The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight AveXis, Passage Bio, Codiak Biosciences. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Medical, Therapeutics. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

Comparing to the other companies, this Boxer Capital performs on 21 percentage points more the average number of lead investments. The increased amount of exits for fund were in 2019. The fund is constantly included in 2-6 deals per year. The important activity for fund was in 2019. Deals in the range of 50 - 100 millions dollars are the general things for fund. Speaking about the real fund results, this VC is 9 percentage points less often commits exit comparing to other organizations.

The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Boxer Capital, startups are often financed by OrbiMed, Vivo Capital, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, Alexandria Venture Investments, Vivo Capital. In the next rounds fund is usually obtained by RA Capital Management, Tavistock Life Sciences, Surveyor Capital.

We also calculated 3 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Boxer Capital:
Typical Co-investors
Boxer Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Boxer Capital:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
724 Solutions Canada, Ontario, Toronto
Carolina Angel Network -
HBM Genomics -
MIT Sandbox Innovation Fund Program Cambridge, Massachusetts, United States
Miteno USA -
My Climate Journey Collective Boston, Massachusetts, United States
Qingdao Machinery Industry General China, Qingdao Shi, Shandong
Sanyo Chemical Industries Japan, Kyoto, Kyoto Prefecture
Tanglin Venture Partners Central Region, Singapore, Singapore
Yi Kong Gao Ke Chengdu Shi, China, Sichuan

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Seismic Therapeutic

$121M04 Dec 2023 -

Alterome Therapeutics

Biopharma
Pharmaceutical
$35M02 Nov 2022 San Diego, California, United States

ARC Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$30M31 Mar 2022 Durham, North Carolina, United States

Seismic Therapeutic

$101M09 Feb 2022 -

Enliven Therapeutics

Biotechnology
Life Science
Therapeutics
$85M19 Jan 2022 Boulder, Colorado, United States

Third Harmonic Bio

Biotechnology
Life Science
$105M16 Jan 2022 Cambridge, Massachusetts, United States

Asher Bio

Biotechnology
Therapeutics
$108M01 Sep 2021 San Francisco, California, United States

Flare Therapeutics

Biotechnology
Health Care
Life Science
$82M13 May 2021 Cambridge, Massachusetts, United States

Nuvalent

Biotechnology
Life Science
Therapeutics
$135M11 May 2021 Cambridge, Massachusetts, United States
News
Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Ajax Therapeutics Raises $40 Million Financing To Develop Novel Small Molecules Targeting Cytokine Signaling Pathways for Hematologic Malignancies

– Ajax Therapeutics, Inc. announced the completion of a $40m financing.
– The round was led by EcoR1 Capital LLC with participation from additional new investor, Boxer Capital, as well as co-founding investors Inning One Ventures and Schrödinger, Inc.
– Existing research collaboration partners, Memorial Sloan Kettering Cancer Center (MSK) and NYU Langone Health, also participated in the financing.
– Concurrent with the financing, Scott Platshon, Partner of EcoR1 Capital, will join the Ajax Board of Directors.
– Proceeds from the financing will support the advancement of Ajax’ lead drug development programs targeting hematologic malignancies.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Boxer Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 81
Average round size 90M
Rounds per year 4.26
Peak activity year 2020
Lead investments 9
Follow on index 0.17
Exits 40
Group Appearance index 0.99

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Seismic Therapeutic

$121M04 Dec 2023 -

Alterome Therapeutics

Biopharma
Pharmaceutical
$35M02 Nov 2022 San Diego, California, United States

ARC Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$30M31 Mar 2022 Durham, North Carolina, United States

Seismic Therapeutic

$101M09 Feb 2022 -

Enliven Therapeutics

Biotechnology
Life Science
Therapeutics
$85M19 Jan 2022 Boulder, Colorado, United States

Third Harmonic Bio

Biotechnology
Life Science
$105M16 Jan 2022 Cambridge, Massachusetts, United States

Asher Bio

Biotechnology
Therapeutics
$108M01 Sep 2021 San Francisco, California, United States

Flare Therapeutics

Biotechnology
Health Care
Life Science
$82M13 May 2021 Cambridge, Massachusetts, United States

Nuvalent

Biotechnology
Life Science
Therapeutics
$135M11 May 2021 Cambridge, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: